See additional questions about Kovaltry®, Jivi® and insurance below.
Bayer has made the decision to discontinue Kogenate FS due to the growing shift in patient use away from older standard half-life products such as Kogenate FS, towards more recent standard and extended half-life products, such as Kovaltry and Jivi.
The timing of discontinuation will vary by Kogenate FS vial size. Customer demand may lead to depletion of the larger vial sizes of Kogenate FS during the fall of 2022. Remaining Kogenate FS vial sizes are anticipated to be available into 2023. For more information on Kogenate FS availability, please reach out to your Bayer rep here, or call Customer Service at 1-888-606-3780.
Our Bayer team is dedicated to ensuring a smooth transition for current Kogenate FS patients, caregivers, and healthcare providers. Call our dedicated Kogenate FS Hotline at 833-40-BAYER to speak to a product specialist for additional information. Your dedicated Bayer rep is also available to answer questions you may have. To get in touch with your Bayer rep, please click here.
Yes, like Kogenate FS, Kovaltry is an unmodified, full-length, standard half-life (SHL) Factor VIII product from Bayer, and offers patients the opportunity to stay on the same dose and frequency of infusions as well as the potential to reduce their dosing frequency. The Kovaltry manufacturing process starts with a cell bank derived from the Kogenate FS cell line, and incorporates advancements to the Kogenate FS manufacturing process which include the removal of human – and animal – derived raw materials from the cell culture and the addition of the 20nm filtration step. Kovaltry is indicated for adults and children with hemophilia A.1,2
Yes, Jivi is an extended half-life (EHL) product offering adult and adolescent patients a twice-weekly starting dose and, based on bleeding episodes, the potential to step up to every 5 days and fine tune. Jivi is indicated for use in previously treated adult and adolescent patients, 12 years of age or older, with hemophilia A and not for use in patients under 12 years of age or in previously untreated patients.3
As a next step, patients should discuss their alternative treatment options with their healthcare provider. As a resource for your patient’s transition, we encourage your patients to download this helpful transition guide. You can also click here to reach out to your Bayer rep for information on our additional hemophilia A treatment options and our patient support services.
Please click here to review clinical trial data from the Kovaltry and Jivi clinical trials, including data on Kogenate FS patients who transitioned to Kovaltry or Jivi. This includes data on patients who treated on-demand and patients who treated with prophylaxis.
Bayer realizes that insurance coverage and patient support programs play an important role when transitioning products. Kovaltry and Jivi are currently covered for 99% of patients nationally.*† Most Kogenate FS patients who transition to Jivi or Kovaltry can receive either product at little to no out of pocket cost, through the Access Services by Bayer program‡§. Access Services by Bayer provides a Patient Loyalty program‡¶, Free Trial program¶#, $0 Co-Pay program‡§, and reimbursement for lab testing‡§.
Yes, Kogenate FS patients who would like to try Kovaltry or Jivi can receive 1 month of free therapy delivered right to their home through the Free Trial Program. Any patient new to Kovaltry or Jivi can participate, regardless of insurance type or status. Click here to learn more about how to enroll your patients in the Free Trial Program¶#.
- Your Bayer rep can also provide Healthcare Providers with in-office trial vials of Kovaltry and Jivi. Please reach out to your Bayer rep here for additional information on this program.